Healthcare - Biotechnology - NASDAQ - GB
$ 3.53
-7.59 %
$ 591 M
Market Cap
-11.77
P/E
BALANCE SHEET
66.5 M
ASSETS
16 M
LIABILITIES
50.5 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Mereo BioPharma Group plc
| Current Assets | 63.8 M |
| Cash & Short-Term Investments | 57.4 M |
| Receivables | 3.73 M |
| Other Current Assets | 2.61 M |
| Non-Current Assets | 2.74 M |
| Long-Term Investments | 0 |
| PP&E | 1.65 M |
| Other Non-Current Assets | 1.09 M |
| Current Liabilities | 9.49 M |
| Accounts Payable | 2.35 M |
| Short-Term Debt | 1.3 M |
| Other Current Liabilities | 5.84 M |
| Non-Current Liabilities | 6.48 M |
| Long-Term Debt | 5.3 M |
| Other Non-Current Liabilities | 1.18 M |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | |
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Cash & Cash Equivalents | 57.4 | 56.3 | 94.3 | 23.5 | 16.3 | 25.0 | 50.0 | 53.6 | 79.7 |
| Short Term Investments | 0 | 51.1 | 0.6 | 0.5 | 0.5 | 2.5 | 2.5 | 0 | 0 |
| Receivables | 3.7 | 2.7 | 1.4 | 1.0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | (2.7) | (1.8) | (4.6) | (12.0) | (0.3) | (2.5) | (53.9) | 0 |
| Other Current Assets | 2.6 | 4.3 | 5.0 | 1.6 | 2.1 | 7.0 | 10.6 | 7.2 | 1.6 |
| Total Current Assets | 63.8 | 62.1 | 99.3 | 29.7 | 30.4 | 34.5 | 63.2 | 60.8 | 81.3 |
| PP&E | 1.6 | 1.8 | 2.5 | 1.6 | 11.6 | 0.1 | 0.2 | 0.2 | 0.2 |
| Intangible Assets | 1.1 | 24.1 | 24.6 | 31.6 | 44.5 | 32.6 | 33.0 | 25.8 | 25.8 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Long Term Assets | 0 | (25.9) | (27.1) | (33.2) | (56.0) | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 66.5 | 88.1 | 126.4 | 62.9 | 86.4 | 67.3 | 96.3 | 86.8 | 107.3 |
| LIABILITIES | |||||||||
| Accounts Payable | 2.3 | 3.5 | 2.3 | 2.9 | 5.9 | 5.6 | 2.6 | 1.2 | 1.1 |
| Short Term Debt | 1.3 | 11.6 | 0.6 | 0.6 | 17.7 | 6.8 | 1.9 | 0 | 0 |
| Other Current Liabilities | 5.2 | 9.4 | 7.9 | 8.0 | 6.1 | 3.6 | 8.3 | 1.9 | 4.8 |
| Total Current Liabilities | 9.5 | 24.7 | 12.5 | 8.6 | 29.9 | 16.2 | 9.6 | 3.2 | 2.8 |
| Long Term Debt | 5.3 | 1.5 | 1.8 | 17.3 | 19.3 | 14.6 | 18.8 | 3.1 | 2.8 |
| Deferred Tax Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 1.2 | 54 K | 36.0 | 60.0 | 24.3 | 3.7 | 5.4 | 1.2 | 0.1 |
| Total Liabilities | 16.0 | 26.2 | 38.4 | 77.9 | 46.2 | 34.5 | 33.9 | 7.5 | 5.8 |
| EQUITY | |||||||||
| Common Stock | 2.8 | 1.9 | 1.8 | 1.0 | 0.3 | 0.2 | 0.2 | 0.2 | 59.2 K |
| Retained Earnings | (419.6) | (331.2) | (297.0) | (309.7) | (146.1) | (111.2) | (79.3) | (33.6) | (12.2) |
| Other Accumulative Comprehensive Income/Loss | (17.5) | 137.9 | 136.9 | 133.2 | 47.3 | 25.6 | 23.4 | 12.7 | 0 |
| Total Equity | 50.5 | 61.9 | 88.0 | (15.0) | 40.3 | 32.8 | 62.5 | 79.3 | 101.5 |
| Total Liabilities and Equity | 66.5 | 88.1 | 126.4 | 62.9 | 86.4 | 67.3 | 96.3 | 86.8 | 107.3 |
| SHARES OUTSTANDING | |||||||||
| Common Shares Outstanding | 659.5 | 603.2 | 527.8 | 337.7 | 89.3 | 71.1 | 69.0 | 44.8 |